• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.64% Nasdaq Down0.55%

    More On DND.TO



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Cipher Pharmaceuticals Inc. (DND.TO)

    14.89 Down 0.64(4.12%) Nov 24
    Add to Portfolio
    ProfileGet Profile for:
    Cipher Pharmaceuticals Inc.
    5650 Tomken Road
    Unit 16
    Mississauga, ON L4W 4P1
    Canada - Map
    Phone: 905-602-5840
    Fax: 905-602-0628
    Website: http://www.cipherpharma.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:N/A

    Business Summary 

    Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical dermatology company in the United States. The company offers CIP-ISOTRETINOIN, a formulation for the treatment of acne; CIP-FENOFIBRATE, a patented formulation of the active ingredient fenofibrate to treat hyperlipidemia; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. It also provides Beteflam Patch, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis; Dermadexin, a topical barrier-repair cream for the treatment of seborrheic dermatitis; and Pruridexin, a topical cream for the treatment of chronic pruritis. In addition, the company is developing Ozenoxacin, which completed Phase III clinical trials to treat adult and paediatric patients with impetigo; ASF-1096, a product candidate in Phase II that is being investigated as a treatment for discoid lupus erythematosus; and CF101, which completed Phase II/III double-blind, placebo-controlled study to treat patients with moderate to severe plaque psoriasis. It has collaborative partnership with Galephar Pharmaceutical Research, Inc. Cipher Pharmaceuticals Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Cipher Pharmaceuticals Inc.

    Key Executives 
    Mr. Shawn Patrick O’Brien ,
    Chief Exec. Officer and Pres
    Mr. Norman Evans CPA, CA, 60
    Chief Financial Officer and Sec.
    Ms. Joan Chypyha ,
    VP of Marketing and Sales
    Ms. Linda Angaritis B.Pharm,
    VP of Global Regulatory Compliance & Quality
    Mr. Peter Weiler M.Sc., M.B.A,
    VP of Bus. Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in CAD.